Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amicus Therapeutics (FOLD) Operating Margin (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Operating Margin for 16 consecutive years, with 8.61% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Margin fell 206.0% year-over-year to 8.61%, compared with a TTM value of 5.17% through Dec 2025, up 46.0%, and an annual FY2025 reading of 5.17%, up 46.0% over the prior year.
  • Operating Margin was 8.61% for Q4 2025 at Amicus Therapeutics, down from 20.27% in the prior quarter.
  • Across five years, Operating Margin topped out at 20.27% in Q3 2025 and bottomed at 95.71% in Q1 2022.
  • Average Operating Margin over 5 years is 29.28%, with a median of 22.53% recorded in 2023.
  • The sharpest move saw Operating Margin tumbled -2492bps in 2022, then surged 5512bps in 2023.
  • Year by year, Operating Margin stood at 87.82% in 2021, then skyrocketed by 45bps to 48.05% in 2022, then surged by 93bps to 3.21% in 2023, then surged by 433bps to 10.67% in 2024, then dropped by -19bps to 8.61% in 2025.
  • Business Quant data shows Operating Margin for FOLD at 8.61% in Q4 2025, 20.27% in Q3 2025, and 6.12% in Q2 2025.